Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Temporal Interference Stimulation Targeting Thalamus for Schizophrenia-Related Cognitive Dysfunction

4 de novembro de 2026 atualizado por: Renrong Wu, Central South University

Therapeutic Efficacy and Mechanism of Temporal Interference Stimulation on Thalamic-Mediated Cognitive Impairment in Schizophrenia

Prefrontal cortical dysfunction in patients with schizophrenia (SCZ) may result from impaired thalamic inputs to this region. Meanwhile, patients with SCZ exhibit a reduced GABA/glutamate ratio in the thalamus, indicating thalamic excitation/inhibition (E/I) imbalance. In addition, SCZ patients show marked reduction of sleep spindles, which are predominantly generated by the thalamic reticular nucleus. Therefore, thalamus-targeted temporal interference stimulation (TIS) may modulate the function of thalamocortical circuits, ameliorate clinical symptoms including cognitive deficits in patients with SCZ, and serve as an effective non-pharmacological intervention. This study consists of two trial components with three objectives: (1) to explore the therapeutic effect of TIS on cognitive function in patients with SCZ; (2) to explore the effect of TIS on positive symptoms in patients with SCZ; (3) to investigate the neural mechanisms underlying TIS-mediated symptom modulation in SCZ.

Trial 1: This study adopts a randomized, controlled, crossover design. Participants will be randomly assigned to two groups: Group A and Group B. Clinical data from 30 patients with schizophrenia (15 participants per group) will be collected, including baseline clinical rating scale scores, cognitive assessments, electroencephalography (EEG), and magnetic resonance imaging (MRI) data. All participants will receive two sessions of TIS intervention in a crossover fashion, with a 1-week washout period between the two interventions. One day prior to each TIS session, participants will complete two training runs of the Sternberg Item-Recognition Paradigm (SIRP) to eliminate confounding learning effects. Outcome measurements including clinical scale scores, cognitive assessments, EEG and MRI data will be acquired at baseline. Task-state MRI will be recorded during both stimulation sessions.

Trial 2: This trial uses a rigorous randomized controlled design. Participants will be randomized into two arms: the TIS group and the control group. Fifty patients with schizophrenia will be enrolled (25 participants per group). Baseline data will be collected, including clinical symptom ratings, cognitive function scores, EEG-derived E/I imbalance metrics, and MRI data. The intervention lasts for 2 weeks with twice-daily stimulation, totaling 20 sessions. Assessments will be performed at baseline, at the end of the 2-week intervention, and at a 4-week post-intervention follow-up to evaluate changes in clinical symptoms, cognition, EEG E/I imbalance, and brain structural and functional features. This trial aims to explore the short-term efficacy, safety, and neurobiological mechanisms of TIS for improving cognitive function in schizophrenia.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

80

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Hunan
      • Changsha, Hunan, China, China 410011
        • Second Xiangya Hospital, Central South University
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18 to 60 years of age
  • meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia as confirmed by the *Structured Clinical Interview for DSM-5* (SCID-5)
  • receiving 1 or 2 antipsychotic medications at a stable dose for at least 1 week before enrollment. Concurrent use of mood stabilizers, antidepressants, or excessive benzodiazepines (lorazepam >2 mg/day) was prohibited,During treatment, the types of antipsychotic drugs remain the same, and the dosage adjustments should not exceed 25%.
  • have functional impairment in daily activities
  • provide written informed consent
  • the disease duration does not exceed 8 years
  • The Global Deficit Score (GDS) for the MATRICS Consensus Cognitive Battery (MCCB) reaches 0.5 or above
  • At least one item of the Positive and Negative Syndrome Scale (PANSS) positive subscale has a score ≥ 4.

Exclusion Criteria:

  • comorbid psychiatric disorders, intellectual disability, clinically significant mood symptoms, or substance use disorders (except caffeine or tobacco)
  • a history of seizures, meningitis, or encephalitis
  • contraindications to transcranial electrical stimulation
  • intracranial tumors or prior neurosurgery
  • a history of severe head trauma
  • receipt of other transcranial electrical or magnetic therapies within 1 month before enrollment
  • with clear drug-induced extrapyramidal reaction

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Group A (A/S): Active stimulation first, followed by sham stimulation

Group A receives active stimulation in the first session and sham stimulation in the second session.One day prior to each TIS session, participants complete two training runs of the Sternberg Item-Recognition Paradigm (SIRP) to eliminate confounding learning effects.Electrodes are placed according to the 10-10 EEG system and secured with conductive paste.Stimulation is individualized based on each participant's Individual Alpha Frequency (IAF). Resting-state EEG is recorded before stimulation to determine the IAF. A continuous high-frequency sinusoidal current pair with a base frequency of 2000 Hz and a beat frequency tuned to the IAF is delivered through each electrode to generate pulsed stimulation for individualized iTBS.Electric field modeling based on T1-weighted MRI images is used to optimize personalized electrode montages, ensuring an electric field strength ≥ 0.2 V/m within the left thalamus for each participant.

Thalamus-targeted temporal interference stimulation delivered via Dome Medical TES NEURO-800, individualized based on individual alpha frequency with electric field optimization from T1 MRI.

Sham temporal interference stimulation with identical setup; current only delivered during brief ramp-up/ramp-down periods to mimic scalp sensation without effective thalamic stimulation.

Comparador Falso: Group B (S/A): Sham stimulation first, followed by active stimulation

Group B receives sham stimulation in the first session and active stimulation in the second session.One day prior to each TIS session, participants complete two training runs of the Sternberg Item-Recognition Paradigm (SIRP) to eliminate confounding learning effects. Electrodes are placed according to the 10-10 EEG system and secured with conductive paste.Stimulation is individualized based on each participant's Individual Alpha Frequency (IAF). Resting-state EEG is recorded before stimulation to determine the IAF. A continuous high-frequency sinusoidal current pair with a base frequency of 2000 Hz and a beat frequency tuned to the IAF is delivered through each electrode to generate pulsed stimulation for individualized iTBS.Electric field modeling based on T1-weighted MRI images is used to optimize personalized electrode montages, ensuring an electric field strength ≥ 0.2 V/m within the left thalamus for each participant.

Thalamus-targeted temporal interference stimulation delivered via Dome Medical TES NEURO-800, individualized based on individual alpha frequency with electric field optimization from T1 MRI.

Sham temporal interference stimulation with identical setup; current only delivered during brief ramp-up/ramp-down periods to mimic scalp sensation without effective thalamic stimulation.

Comparador Falso: sham group:Sham TIS

Participants in the sham group receive sham TIS following the identical schedule: two sessions daily for 10 days, 20 sessions in total. The sham paradigm uses the same 2000 Hz current pair. Current is only delivered during the 10-second ramp-up and ramp-down phases at the start and end of each session, while no current is applied during the middle period. This setup mimics the scalp tingling sensation induced by current changes at the beginning and end of active stimulation. All other hardware, electrode placement and study procedures are identical to the active TIS group.

Sham temporal interference stimulation with identical setup; current only delivered during brief ramp-up/ramp-down periods to mimic scalp sensation without effective thalamic stimulation.

Experimental: TIS group:TIS

Participants in the TIS group receive active TIS stimulation, with two intervention sessions per day for 10 consecutive days, totaling 20 sessions. Each session lasts 30 minutes. Electrodes are placed according to the 10-10 EEG system and secured with conductive paste. Stimulation is individualized based on each participant's Individual Alpha Frequency (IAF). Resting-state EEG is recorded before stimulation to determine the IAF. A continuous high-frequency sinusoidal current pair with a base frequency of 2000 Hz and a beat frequency tuned to the IAF is delivered through each electrode to generate pulsed stimulation for individualized iTBS. Electric field modeling based on T1-weighted MRI images is used to optimize personalized electrode montages, ensuring an electric field strength ≥ 0.2 V/m within the left thalamus for each participant. Each stimulation session lasts 30 minutes, with a 10-second ramp-up period at the onset and a 10-second ramp-down period at the end.

Thalamus-targeted temporal interference stimulation delivered via Dome Medical TES NEURO-800, individualized based on individual alpha frequency with electric field optimization from T1 MRI.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Changes in brain function
Prazo: baseline (T1 structural scan); pre-, during, and post-first stimulation (Day 1); pre-, during, and post-second stimulation (Day 9)

Functional MRI (fMRI) is based on the blood oxygen level dependent (BOLD) contrast that can detect changes in blood oxygenation to analyze the change of brain function after intervention.This outcome is for sub-trial 1 (single-session crossover TIS).

baseline (T1 structural scan); pre-, during, and post-first stimulation (Day 1); pre-, during, and post-second stimulation (Day 9)
changes on the MATRICS Consensus Cognitive Battery (MCCB) scores
Prazo: baseline,2 week visit, 4-week follow-up visit

The MATRICS Consensus Cognitive Battery (MCCB) can be used for cognitive assessment of schizophrenia, bipolar disorder, and other neuropsychiatric diseases. The MCCB covers nine cognitive domains, including attention, information processing speed, verbal learning and memory, visual learning and memory, spatial working memory, reasoning, problem solving, social cognition, executive function, and fine motor skills. The working memory domain does not include verbal working memory because the Chinese language would not make feasible the inclusion of the LNS test.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline,2 week visit, 4-week follow-up visit

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Changes in Positive and Negative Symptom Scale-6 (PANSS-6) scores
Prazo: pre-and post-first stimulation (Day 1); pre- and post-second stimulation (Day 9)

The PANSS-6 is a shortened version of the Positive and Negative Syndrome Scale for assessment of psychotic symptoms in schizophrenia. Scores range from 6 to 42, higher score indicates more severe psychotic symptoms. This outcome is for sub-trial 1 (single-session crossover TIS).

pre-and post-first stimulation (Day 1); pre- and post-second stimulation (Day 9)
Change in brain responses during the Sternberg Item-Recognition Paradigm (SIRP)
Prazo: pre-, during, and post-first stimulation (Day 1); pre-, during, and post-second stimulation (Day 9)

The Sternberg Item-Recognition Paradigm (SIRP) is a task fMRI paradigm for evaluating working memory processing. T1-weighted structural MRI at baseline is acquired for individual brain modeling. Task fMRI scans are obtained pre-stimulation, during stimulation, and post-stimulation for each session. This outcome is for sub-trial 1 (single-session crossover TIS).

pre-, during, and post-first stimulation (Day 1); pre-, during, and post-second stimulation (Day 9)
Changes in brain function
Prazo: baseline, 2-week visit (end of intervention)

Functional MRI (fMRI) is based on the blood oxygen level dependent (BOLD) contrast that can detect changes in blood oxygenation to analyze the change of brain function after intervention.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Change in PANSS total scores
Prazo: baseline, 2-week visit (end of intervention), 4-week follow-up visit

The Positive and Negative Syndrome Scale (PANSS) is widely used to assess positive, negative and general psychopathology symptoms of schizophrenia. Scores range from 30 to 210, higher score indicates more severe positive and negative symptoms. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention), 4-week follow-up visit
Change in PSYRATS scores
Prazo: baseline, 2-week visit (end of intervention), 4-week follow-up visit

The Psychotic Symptoms Rating Scale (PSYRATS) quantifies the severity and dimensional features of hallucinations and delusions in patients with psychosis. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention), 4-week follow-up visit
Change in SANS scores
Prazo: baseline, 2-week visit (end of intervention), 4-week follow-up visit

The Scale for the Assessment of Negative Symptoms (SANS) evaluates the severity of negative symptoms in schizophrenia, including affective flattening, alogia, avolition-apathy, anhedonia-asociality and attentional impairment. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention), 4-week follow-up visit
Change in GAF scores
Prazo: baseline, 2-week visit (end of intervention), 4-week follow-up visit

The Global Assessment of Functioning (GAF) scale rates overall psychological, social and occupational functioning. Scores range from 0 to 100, higher score represents better functional status. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention), 4-week follow-up visit
Change in Global Functioning Scale (GFS) scores
Prazo: baseline, 4-week follow-up visit

The Global Functioning Scale (GFS) assesses real-world social and role functioning among individuals with severe mental disorders. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit
Change in Social Functioning Scale (SFS) scores
Prazo: baseline,4-week follow-up visit

The Social Functioning Scale (SFS) measures multiple domains of social functioning for patients with schizophrenia spectrum disorders. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline,4-week follow-up visit
Change in brain responses during the 2-back task fMRI paradigm
Prazo: 2-week visit (end of intervention)

Task fMRI based on the 2-back working memory paradigm used to assess working memory-related thalamocortical brain activity. High-resolution T1-weighted structural MRI at baseline is acquired for individual brain modeling. This outcome is for sub-trial 2 (2-week repeated TIS).

2-week visit (end of intervention)
Change in 1/f aperiodic EEG signal (E/I balance index)
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

The 1/f aperiodic signal of resting-state electroencephalography is measured as an index of excitation-inhibition (E/I) balance. This outcome is for sub-trial 2 (2-week repeated TIS).This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in long-range temporal correlation (LRTC) of resting EEG
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

Long-range temporal correlation (LRTC) of resting-state electroencephalography is measured as an index of excitation-inhibition (E/I) balance.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in functional E/I ratio (fE/I) of resting EEG
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

Functional E/I ratio (fE/I) from resting-state electroencephalography is measured as an index of excitation-inhibition (E/I) balance.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in gamma oscillatory power of resting EEG
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

Gamma-band oscillatory power of resting-state electroencephalography is measured as an index of excitation-inhibition (E/I) balance.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in beta oscillatory power of resting EEG
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

Beta-band oscillatory power of resting-state electroencephalography is measured as an index of excitation-inhibition (E/I) balance.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in 40 Hz auditory steady-state response (40 Hz-ASSR)
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

40 Hz auditory steady-state response (40 Hz-ASSR) is recorded by electroencephalography for excitation-inhibition balance assessment.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in mismatch negativity (MMN) amplitude
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

Mismatch negativity (MMN) is recorded by electroencephalography for excitation-inhibition balance assessment.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Change in P50 sensory gating ratio
Prazo: baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit

P50 sensory gating ratio is recorded by electroencephalography for sensory gating assessment.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, after first stimulation,2-week visit (end of intervention), 4-week follow-up visit
Sleep spindle density from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Sleep spindle density is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Sleep spindle frequency from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Sleep spindle frequency is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Sleep spindle amplitude from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Sleep spindle amplitude is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Sleep spindle duration from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Sleep spindle duration is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Slow oscillation power from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Slow oscillation power is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Slow oscillation amplitude from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Slow oscillation amplitude is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Slow oscillation slope from sleep EEG
Prazo: baseline, 2-week visit (end of intervention)

Slow oscillation slope is derived from sleep electroencephalography.This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 2-week visit (end of intervention)
Change in routine blood test parameters
Prazo: baseline, 4-week follow-up visit

Approximately 10 mL of intravenous blood is collected (2 mL whole blood, 4 mL serum, 4 mL plasma) at baseline and 4-week follow-up. Samples are sent to the clinical laboratory of the Second Xiangya Hospital, Central South University for routine blood examination. Samples are destroyed immediately after testing, and test data are limited for use by the Second Xiangya Hospital, Central South University. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit
Change in liver function parameters
Prazo: baseline, 4-week follow-up visit

Approximately 10 mL of intravenous blood is collected (2 mL whole blood, 4 mL serum, 4 mL plasma) at baseline and 4-week follow-up. Samples are sent to the clinical laboratory of the Second Xiangya Hospital, Central South University for liver function testing. Samples are destroyed immediately after testing, and test data are limited for use by the Second Xiangya Hospital, Central South University. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit
Change in renal function parameters
Prazo: baseline, 4-week follow-up visit

Approximately 10 mL of intravenous blood is collected (2 mL whole blood, 4 mL serum, 4 mL plasma) at baseline and 4-week follow-up. Samples are sent to the clinical laboratory of the Second Xiangya Hospital, Central South University for renal function testing. Samples are destroyed immediately after testing, and test data are limited for use by the Second Xiangya Hospital, Central South University. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit
Change in blood lipid levels
Prazo: baseline, 4-week follow-up visit

Approximately 10 mL of intravenous blood is collected (2 mL whole blood, 4 mL serum, 4 mL plasma) at baseline and 4-week follow-up. Samples are sent to the clinical laboratory of the Second Xiangya Hospital, Central South University for blood lipid testing. Samples are destroyed immediately after testing, and test data are limited for use by the Second Xiangya Hospital, Central South University. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit
Change in fasting plasma glucose concentration
Prazo: baseline, 4-week follow-up visit

Approximately 10 mL of intravenous blood is collected (2 mL whole blood, 4 mL serum, 4 mL plasma) at baseline and 4-week follow-up. Samples are sent to the clinical laboratory of the Second Xiangya Hospital, Central South University for fasting glucose testing. Samples are destroyed immediately after testing, and test data are limited for use by the Second Xiangya Hospital, Central South University. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit
Change in peripheral inflammatory factor concentrations
Prazo: baseline, 4-week follow-up visit

Approximately 10 mL of intravenous blood is collected (2 mL whole blood, 4 mL serum, 4 mL plasma) at baseline and 4-week follow-up. Samples are sent to the clinical laboratory of the Second Xiangya Hospital, Central South University for inflammatory factor testing. Samples are destroyed immediately after testing, and test data are limited for use by the Second Xiangya Hospital, Central South University. This outcome is for sub-trial 2 (2-week repeated TIS).

baseline, 4-week follow-up visit

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Renrong Wu, Second Xiangya Hospital of Central South University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

1 de outubro de 2027

Conclusão do estudo (Estimado)

31 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

28 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

4 de novembro de 2026

Primeira postagem (Real)

10 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever